Cargando…
CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma
BACKGROUND: Cell division cycle 6 (CDC6) is a key licensing factor in the assembly of pre-replicative complexes at origins of replication. The role of CDC6 in the pathogenesis of in diffuse larger B-cell lymphoma (DLBCL) remains unknown. We aim to investigate the effects of CDC6 on the proliferation...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571299/ https://www.ncbi.nlm.nih.gov/pubmed/37833632 http://dx.doi.org/10.1186/s12885-023-11186-6 |
_version_ | 1785119958553853952 |
---|---|
author | Shen, Mingfang Zhang, Yunfeng Tang, Lun Fu, Qinyan Zhang, Jiawei Xu, Yang Zeng, Hui Li, Yuan |
author_facet | Shen, Mingfang Zhang, Yunfeng Tang, Lun Fu, Qinyan Zhang, Jiawei Xu, Yang Zeng, Hui Li, Yuan |
author_sort | Shen, Mingfang |
collection | PubMed |
description | BACKGROUND: Cell division cycle 6 (CDC6) is a key licensing factor in the assembly of pre-replicative complexes at origins of replication. The role of CDC6 in the pathogenesis of in diffuse larger B-cell lymphoma (DLBCL) remains unknown. We aim to investigate the effects of CDC6 on the proliferation, apoptosis and cell cycle regulation in DLBCL cells, delineate its underlying mechanism, and to correlate CDC6 expression with clinical characteristics and prognosis of patients with DLBCL. METHODS: Initial bioinformatic analysis was performed to screen the potential role of CDC6 in DLBCL. Lentiviral constructs harboring CDC6 or shCDC6 was transfected to overexpress or knockdown CDC6 in SUDHL4 and OCI-LY7 cells. The cell proliferation was evaluated by CCK-8 assay, cell apoptosis was detected by Annexin-V APC/7-AAD double staining, and cell cycle was measured by flow cytometry. Real time quantitative PCR and western blot was used to characterize CDC6 expression and its downstream signaling pathways. The clinical data of DLBCL patients were retrospectively reviewed, the CDC6 expression in DLBCL or lymph node reactive hyperplasia tissues was evaluated by immunohistochemistry. RESULTS: In silico data suggest that CDC6 overexpression is associated with inferior prognosis of DLBCL. We found that CDC6 overexpression increased SUDHL4 or OCI-LY7 cell proliferation, while knockdown of CDC6 inhibited cell proliferation in a time-dependent manner. Upon overexpression, CDC6 reduced cells in G1 phase and did not affect cell apoptosis; CDC6 knockdown led to significant cell cycle arrest in G1 phase and increase in cell apoptosis. Western blot showed that CDC6 inhibited the expression of INK4, E-Cadherin and ATR, accompanied by increased Bcl-2 and deceased Bax expression. The CDC6 protein was overexpressed DLBCL compared with lymph node reactive hyperplasia, and CDC6 overexpression was associated with non-GCB subtype, and conferred poor PFS and OS in patients with DLBCL. CONCLUSION: CDC6 promotes cell proliferation and survival of DLBCL cells through regulation of G1/S cell cycle checkpoint and apoptosis. CDC6 is overexpressed and serves as a novel prognostic marker in DLBCL. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11186-6. |
format | Online Article Text |
id | pubmed-10571299 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105712992023-10-14 CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma Shen, Mingfang Zhang, Yunfeng Tang, Lun Fu, Qinyan Zhang, Jiawei Xu, Yang Zeng, Hui Li, Yuan BMC Cancer Research BACKGROUND: Cell division cycle 6 (CDC6) is a key licensing factor in the assembly of pre-replicative complexes at origins of replication. The role of CDC6 in the pathogenesis of in diffuse larger B-cell lymphoma (DLBCL) remains unknown. We aim to investigate the effects of CDC6 on the proliferation, apoptosis and cell cycle regulation in DLBCL cells, delineate its underlying mechanism, and to correlate CDC6 expression with clinical characteristics and prognosis of patients with DLBCL. METHODS: Initial bioinformatic analysis was performed to screen the potential role of CDC6 in DLBCL. Lentiviral constructs harboring CDC6 or shCDC6 was transfected to overexpress or knockdown CDC6 in SUDHL4 and OCI-LY7 cells. The cell proliferation was evaluated by CCK-8 assay, cell apoptosis was detected by Annexin-V APC/7-AAD double staining, and cell cycle was measured by flow cytometry. Real time quantitative PCR and western blot was used to characterize CDC6 expression and its downstream signaling pathways. The clinical data of DLBCL patients were retrospectively reviewed, the CDC6 expression in DLBCL or lymph node reactive hyperplasia tissues was evaluated by immunohistochemistry. RESULTS: In silico data suggest that CDC6 overexpression is associated with inferior prognosis of DLBCL. We found that CDC6 overexpression increased SUDHL4 or OCI-LY7 cell proliferation, while knockdown of CDC6 inhibited cell proliferation in a time-dependent manner. Upon overexpression, CDC6 reduced cells in G1 phase and did not affect cell apoptosis; CDC6 knockdown led to significant cell cycle arrest in G1 phase and increase in cell apoptosis. Western blot showed that CDC6 inhibited the expression of INK4, E-Cadherin and ATR, accompanied by increased Bcl-2 and deceased Bax expression. The CDC6 protein was overexpressed DLBCL compared with lymph node reactive hyperplasia, and CDC6 overexpression was associated with non-GCB subtype, and conferred poor PFS and OS in patients with DLBCL. CONCLUSION: CDC6 promotes cell proliferation and survival of DLBCL cells through regulation of G1/S cell cycle checkpoint and apoptosis. CDC6 is overexpressed and serves as a novel prognostic marker in DLBCL. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11186-6. BioMed Central 2023-10-13 /pmc/articles/PMC10571299/ /pubmed/37833632 http://dx.doi.org/10.1186/s12885-023-11186-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Shen, Mingfang Zhang, Yunfeng Tang, Lun Fu, Qinyan Zhang, Jiawei Xu, Yang Zeng, Hui Li, Yuan CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma |
title | CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma |
title_full | CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma |
title_fullStr | CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma |
title_full_unstemmed | CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma |
title_short | CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma |
title_sort | cdc6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large b-cell lymphoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571299/ https://www.ncbi.nlm.nih.gov/pubmed/37833632 http://dx.doi.org/10.1186/s12885-023-11186-6 |
work_keys_str_mv | AT shenmingfang cdc6akeyreplicationlicensingfactorisoverexpressedandconferspoorprognosisindiffuselargebcelllymphoma AT zhangyunfeng cdc6akeyreplicationlicensingfactorisoverexpressedandconferspoorprognosisindiffuselargebcelllymphoma AT tanglun cdc6akeyreplicationlicensingfactorisoverexpressedandconferspoorprognosisindiffuselargebcelllymphoma AT fuqinyan cdc6akeyreplicationlicensingfactorisoverexpressedandconferspoorprognosisindiffuselargebcelllymphoma AT zhangjiawei cdc6akeyreplicationlicensingfactorisoverexpressedandconferspoorprognosisindiffuselargebcelllymphoma AT xuyang cdc6akeyreplicationlicensingfactorisoverexpressedandconferspoorprognosisindiffuselargebcelllymphoma AT zenghui cdc6akeyreplicationlicensingfactorisoverexpressedandconferspoorprognosisindiffuselargebcelllymphoma AT liyuan cdc6akeyreplicationlicensingfactorisoverexpressedandconferspoorprognosisindiffuselargebcelllymphoma |